Clinical Trial Update: Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 [Phase 4]

View source ↗

Summary

Phase 4 trial comparing weight-adjusted versus fixed low-dose low molecular weight heparin for venous thromboembolism prevention in COVID-19, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: COVID, Thrombosis | Phase 4 | Status: COMPLETED